Abstract
Immunohistochemically detected over-expression of P53-related protein (P53+++) and absence of P21(waf1) expression (P21-) correspond to loss of function of the P53-gene in diffuse large B-cell lymphoma (DLBCL) patients. Using immunohistochemistry we examined 80 patients with DLBCL and found that 23% had the P53+++/P21- phenotype while 51% had a germinal center (GC) pattern. Both the P53+++/P21- phenotype and the non-GC pattern were associated with inferior outcome. Notably, the prognostic power of the P53+++/P21- phenotype was restricted to patients with a GC pattern, without effect on outcome of patients with a non-GC phenotype. Our results show that immunohistochemistry can parallel gene expression profiling in addressing clinical variability of DLBCL patients.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Bleomycin / administration & dosage
-
Cell Cycle / genetics
-
Cohort Studies
-
Cyclin-Dependent Kinase Inhibitor p21 / analysis
-
Cyclin-Dependent Kinase Inhibitor p21 / deficiency*
-
Cyclin-Dependent Kinase Inhibitor p21 / genetics
-
Cyclophosphamide / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Epirubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Genes, p53
-
Germinal Center / pathology
-
Humans
-
Immunohistochemistry
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Lymphoma, Large B-Cell, Diffuse / radiotherapy
-
Male
-
Middle Aged
-
Neoplasm Proteins / analysis*
-
Neoplasm Proteins / deficiency
-
Neoplasm Proteins / genetics
-
Phenotype
-
Prednisone / administration & dosage
-
Prognosis
-
Radiotherapy, Adjuvant
-
Reproducibility of Results
-
Rituximab
-
Survival Analysis
-
Survival Rate
-
Tumor Suppressor Protein p53 / analysis*
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
CDKN1A protein, human
-
Cyclin-Dependent Kinase Inhibitor p21
-
Neoplasm Proteins
-
Tumor Suppressor Protein p53
-
Bleomycin
-
Epirubicin
-
Rituximab
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone
Supplementary concepts
-
CEOP protocol 1
-
CHOP protocol
-
VACOP-B protocol